Full Text
EE500 Cost-Effectiveness Analysis of Cemiplimab As Second-Line Therapy for Recurrent Cervical Cancer in Japan

Abstract

Authors

Y.T. Shibata Maeda W. Chen K. Morimoto K. Moriwaki K. Shimozuma

Back to Volume 26, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×